Gastrointestinal Cancer

Diagnostic Pitfalls and Challenges in Hepatocellular Carcinoma

This one-hour CME/CMLE credit-bearing case-based online module will provide the latest guidance to the laboratory team in providing the most accurate recommendations for testing as members of the multidisciplinary hepatocellular carcinoma (HCC) cancer treatment team.

This activity addresses the following topics:

• Liver tissue acquisition
• HCC diagnostic challenges
• IHC and ISH staining techniques to resolve common differential diagnoses
• HCC biomarkers

Biomarker Testing in Colorectal Cancer

This one-hour CME/CMLE credit-bearing activity will provide guidance to members of the laboratory team on how to develop and implement guideline-driven biomarker testing protocols for patients with metastatic colorectal cancer (mCRC).

This activity addresses the following topics:

• NCCN guidelines for biomarker testing for patients with mCRC
• Considerations to optimize fixation, IHC, and molecular testing in patients with mCRC
• Techniques for optimizing the interpretation and communication of biomarker testing results
• New and emerging therapies for patients with mCRC
• The importance of effective communication and a team-based approach in the diagnosis and management of patients with mCRC to optimize evidence-based clinical decision-making

Online Tumor Board Simulation: Optimizing Testing and Treatment of Patients with BRAF^V600E-mutant mCRC in Community Practice

This 60-minute self-paced online tumor board will help pathologists and laboratory professionals, particularly those in community practice, gain deeper scientific knowledge and skills in diagnosing, testing, and treating patients with BRAF-mutant metastatic colorectal cancer (mCRC). Throughout the online tumor board simulation, learners will answer questions designed to help them carefully consider the nuances of each case, building their knowledge and skills related to the detection and optimal management of patients with BRAF-mutant mCRC.

Topics covered include the following:

• NCCN guidelines for conducting biomarker testing, including BRAF testing, for patients with mCRC
• The importance of conducting biomarker testing at the time of diagnosis
• Considerations to optimize fixation and IHC and molecular testing for BRAF mutations in patients with mCRC
• Interpretation and communication of BRAF testing results
• Opportunities for improving turnaround time in molecular testing in mCRC, including current and emerging testing platforms
• Clinicopathologic characteristics of BRAF-mutant mCRC
• New and emerging therapies for patients with BRAF-mutant mCRC
• The importance of effective communication and a team-based approach in the diagnosis and management of patients with mCRC to optimize evidence-based clinical decision-making

Multidisciplinary Approach to Diagnosis and Biomarker Testing in Gastrointestinal Cancer

Recorded February 15, 2022

This 60-minute on-demand webcast highlights practice-changing developments in gastrointestinal biomarker testing and treatment, including new clinical data with immediate implications for patient care. Using a case-based approach, an expert GI pathologist and oncologist will help you learn optimal testing, interpreting findings, individualized treatment, and sequencing strategies for gastrointestinal cancers.

Topics include:

• Biomarkers and the use of molecular testing to guide therapy selection in patients with advanced colorectal, pancreatic, biliary, gastric, esophageal, and gastroesophageal junction cancers, such as:
  • BRAF V600E, BRCA1/2, HER2/HER3, BRAF V600E, IDH1, and FGFR2
  • Tumor agnostic biomarkers, such as MMR/MSI, NTRK, and TMB
  • Emerging biomarkers
• Emerging assays in GI cancers, such as liquid biopsy